LAPTM4B and non-small cell lung carcinoma: Interestingly, MDA levels significantly increased in LAPTM4B KO H1299 cells (approximately 62.4%) and in LAPTM4B KO A549 cells (approximately 24.2%), indicating that LAPTM4B is capable of suppressing lipid peroxidation in NSCLC (Fig. 2D).